RFP - 2-PAM Autoinjectors for Project Bioshield (PBS)

BARDA seeks late-stage clinical development, regulatory approval for 2-PAM autoinjectors (as a drug/device combination product) to treat organophosphate (OP) poisoning, including nerve agents, in adult and pediatric populations, and procurement of 2-PAM autoinjectors for the SNS/CHEMPACK Program.

• NAICS541714
• PSCAB12

• 06 RFP_PBS_2PAM_2026_Final.pdf

  .pdf1.5 MB
  Download

• Erin Greninger, Contracting Officer
  erin.greninger@hhs.gov
• Greg Smith
  greg.smith1@hhs.gov